Regarding the study population, the KRAS mutation prevalence was consistent with the literature, with almost 40% of CRC cases being KRAS mutant and with a distribution of mutations that is similar to the results reported worldwide [31,32]. The gene discussed is KRAS; the disease is colorectal carcinoma.